Gossamer Bio Faces Shareholder Investigation Following Disappointing Trial Results
New York, NY – March 23, 2026 – Levi & Korsinsky, LLP has announced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) regarding potential violations of federal securities laws. The investigation stems from concerns surrounding the Phase 3 PROSERA study of seralutinib, the company’s lead pipeline candidate for pulmonary arterial hypertension (PAH).
PROSERA Trial and Prior Optimistic Statements
The PROSERA study, designed to evaluate seralutinib in patients with PAH, did not achieve its primary efficacy endpoint, failing to reach the prespecified level of statistical significance. This outcome contrasts with prior statements made by Gossamer Bio’s management regarding the trial’s prospects.
During the Q1 2025 earnings call on May 15, 2025, CEO Faheem Hasnain expressed strong confidence in the trial, stating that the baseline characteristics of enrolled patients were “precisely what we have targeted” and that the company was “more optimistic than ever about the likelihood of achieving positive results.” Management similarly claimed “over 90% power given the sample size.”
Investigation Focus
Levi & Korsinsky is investigating whether Gossamer Bio’s previous statements to investors concerning trial confidence, statistical power and patient baseline characteristics were accurate. The firm is particularly scrutinizing the discrepancy between the optimistic projections and the ultimate trial results, where the p-value of 0.032 failed to meet the prespecified significance threshold of 0.025.
Investor Claims and Legal Representation
Investors who suffered losses on their Gossamer Bio, Inc. Securities are encouraged to explore potential recovery options under federal securities laws. Levi & Korsinsky is offering legal representation to affected shareholders.
Those interested in learning more about the investigation or discussing their legal rights can contact Joseph E. Levi, Esq. Via email at jlevi@levikorsinsky.com or by phone at (212) 363-7500.
About Levi & Korsinsky, LLP
Levi & Korsinsky LLP has a 20-year track record of securing hundreds of millions of dollars for aggrieved shareholders in securities litigation. The firm has been consistently recognized for its expertise, ranking in ISS Securities Class Action Services’ Top 50 Report for seven consecutive years. Levi & Korsinsky has a team of over 70 employees dedicated to serving its clients.
Attorney Advertising. Prior results do not guarantee similar outcomes.